LILRA1: A Promising Drug Target for Immune and Inflammatory Disorders

Target Name: LILRA1

NCBI ID: G11024

LILRA1

LILRA1: A Promising Drug Target for Immune and Inflammatory Disorders

LILRA1 (Long Interleukin-2 Receptor-1) is a protein that is expressed in a variety of tissues throughout the body, including the immune system, skin, and nervous system. It is a member of the IL-2 receptor family, which is a group of proteins that play a critical role in the regulation of immune and inflammatory responses.

One of the things that makes LILRA1 an interesting drug target is its location on the cell surface. LILRA1 is expressed in the cytoplasm of cells, which makes it relatively easy to target with small molecules or antibodies. Additionally, LILRA1 is a protein that is highly Transmembrane, which means it can be easily manipulated on the surface of the cell.

Another reason why LILRA1 is an attractive drug target is its role in the regulation of immune responses. LILRA1 is involved in the development and maintenance of CD8+ T cells, which are a crucial part of the immune system. CD8+ T cells are responsible for recognizing and destroying infected or abnormal cells in the body, and LILRA1 plays a key role in this process.

In addition to its role in immune function, LILRA1 is also involved in the regulation of inflammation. When inflammation is present, LILRA1 helps to control the amount of inflammation that occurs in the body. This is important because chronic inflammation can contribute to a variety of diseases, including heart disease, diabetes, and cancer.

Another potential mechanism by which LILRA1 may be involved in the development of cancer is its role in cell signaling. LILRA1 is a potent negative regulator of the NF-kappa-B signaling pathway, which is a critical pathway involved in the regulation of cell behavior and function. This means that when NF-kappa-B signaling is active, LILRA1 works to inhibit it, which can help to prevent the development of cancer.

In addition to its potential role in cancer development, LILRA1 may also be involved in the regulation of other processes in the body. For example, LILRA1 has been shown to play a key role in the regulation of skin cell development and differentiation, and it is involved in the development of hair and nails. It may also be involved in the regulation of neurotransmitter release and the modulation of pain perception.

Given its involvement in a variety of processes in the body, LILRA1 is an attractive drug target for researchers to explore. There is a growing body of research that has identified potential small molecules that can inhibit LILRA1 activity, and these molecules have the potential to be used to treat a wide range of diseases. For example, LILRA1 has been shown to be involved in the regulation of skin aging and has been shown to be a potential therapeutic target for the treatment of skin diseases such as acne and rosacea.

In addition to its potential therapeutic applications, LILRA1 is also an important biomarker for a variety of diseases. For example, LILRA1 has been shown to be involved in the regulation of skin aging and has been used as a biomarker for the diagnosis of age-related diseases such as wrinkles and fine lines. It may also be used as a biomarker for other diseases, such as cancer and neurodegenerative diseases.

Overall, LILRA1 is an interesting drug target due to its location on the cell surface, its role in immune and inflammatory responses, and its potential involvement in the regulation of cell signaling pathways. Further research is needed to fully understand the potential mechanisms of LILRA1 and its potential therapeutic applications.

Protein Name: Leukocyte Immunoglobulin Like Receptor A1

Functions: May act as receptor for class I MHC antigens

The "LILRA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LILRA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets